This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by RENDELL, M. Search for Related Content PubMed PubMed Citation Articles by RENDELL, M.

C-Peptide Levels as a Criterion in Treatment of Maturity-Onset Diabetes

The Johns Hopkins University School of Medicine Baltimore, Maryland 21205

Address requests for reprints to Dr. Marc Rendell.

C-Peptide levels, both basal and glucose-stimulated, were contrasted in diet-controllable vs. nondiet-controllable maturity-onset diabetic patients. Fasting and glucose-stimulated plasma C-peptide values in diet-controlled diabetics were similar to those in normal subjects. Diabetic patients who were not solely diet controllable could be differentiated into two subgroups. One diet failure subgroup was truly insulin dependent, in that insulin treatment could not be stopped for even a brief period. In these patients, fasting C-peptide levels were very low, in the same range as in the majority of juvenile-onset diabetic patients. In the second diet failure subgroup, it was possible to manage patients without insulin therapy for varying periods of time, although most patients eventually needed insulin. Fasting C-peptide levels in this second subgroup were also in the same range as those in normal subjects. However, their C-peptide responses to glucose were significantly blunted. Measurement of C-peptide may furnish a useful criterion for the categorization of maturity-onset diabetic patients. Furthermore, C-peptide levels help considerably in the selection of treatment modalities for these patients. Low C-peptide levels identify those patients who require insulin treatment, whereas high C-peptide levels in insulin-treated patients suggest the possibility of discontinuing insulin.

^* Present address: Diabetes Institute, City df Faith Medical and Research Center, Oral Roberts University School of Medicine, Tulsa, Oklahoma 74171.

Received January 27, 1983.

This article has been cited by other articles:

				M. Rendell Dietary Treatment of Diabetes Mellitus N. Engl. J. Med., May 11, 2000; 342(19): 1440 - 1441. [Full Text]

				L. M. Frazier, C. D. Mulrow, L. T. Alexander Jr, R. T. Harris, K. R. Heise, J. T. Brown, and J. R. Feussner Need for Insulin Therapy in Type II Diabetes Mellitus: A Randomized Trial Arch Intern Med, June 1, 1987; 147(6): 1085 - 1089. [Abstract] [PDF]

				K. Osei Clinical Evaluation of Determinants of Glycemic Control: A New Approach Using Serum Glucose, C-Peptide, and Body Mass Indexes in Type II Diabetic Patients Arch Intern Med, February 1, 1986; 146(2): 281 - 285. [Abstract] [PDF]